Clinical Trial

SGLT2i, Pioglitazone, and Ketone Production in T2D

Name: SGLT2i, Pioglitazone, and Ketone Production in T2D — clinical trial record (NCT07053319)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

To examine whether the empagliflozin-induced stimulation of EGP, lipolysis, and ketone production in T2D individuals can be blocked by pioglitazone (which has direct hepatic and adipose tissue effects).

Protocol Amendment History 1 change

minor Trial arms changed: 4 -> 3 2026-07-19

Trial Details

NCT Number	NCT07053319
Lead Sponsor	The University of Texas Health Science Center at San Antonio Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions	Type 2 Diabetes
Enrollment	64 participants
Start Date	2026-05-11
Primary Completion	2027-06-01 (estimated)
Study Completion	2027-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-17